StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Seattle Genetics (SGEN) Initiates New Phase 1 Study in R/R Multiple Myeloma
March 7, 2018 8:03 AM
Seattle Genetics, Inc. (NASDAQ: SGEN) today announced dosing of the first patient in a phase 1 clinical trial evaluating the ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Corporate News
Management Comments
Next Articles
Seattle Genetics Initiates New Phase 1 Study in Relapsed or Refractory Multiple Myeloma
March 7, 2018 8:00 AM